Physician profile
Catherine Ellis
NPI 1548473150
$1,733.11
in general payments reported to CMS, 2019-2025
25 companies · $608 in 2025
The $608 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $16.45 · 2021: $53.91 · 2022: $74.95 · 2023: $159 · 2024: $236 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962 · Education: $41.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.54 |
| Education | $41.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $255.36 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $243.65 | 2019-2025 | Tepezza, Evenity, Prolia |
| Lilly USA, LLC | $143.95 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $121.84 | 2023-2025 | Freestyle Libre 3 |
| Genzyme Corporation | $110.00 | 2019 | |
| Radius Health, INC. | $105.67 | 2023-2025 | Tymlos |
| Insulet Corporation | $83.48 | 2025 | Omnipod |
| Ibsa Pharma INC. | $71.86 | 2019 | |
| Amneal Pharmaceuticals LLC | $70.69 | 2021-2025 | Unithroid |
| Medtronic, INC. | $65.98 | 2025 | Minimed 780g |
| Antares Pharma, INC. | $60.43 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.67 | 2019 | |
| Shire North American Group INC | $50.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.86 | 2019 | |
| Sanofi-Aventis U.S. LLC | $35.35 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $31.80 | 2025 | Senza |
| Valeritas, INC. | $25.71 | 2019 | |
| Fidia Pharma USA INC. | $25.36 | 2025 | Hymovis |
| Merck Sharp & Dohme LLC | $24.37 | 2019 | |
| Corcept Therapeutics | $24.01 | 2021 | |
| Horizon Therapeutics Plc | $20.96 | 2023 | Tepezza |
| Medtronic Minimed, INC. | $20.88 | 2019 | |
| Kyowa Kirin, INC. | $18.57 | 2023 | |
| Tandem Diabetes Care, INC. | $16.45 | 2020 | |
| Vivus LLC | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.